FAKTOR-OPTIONSSCHEIN - DERMAPHARM HOLDING Share Price

Certificat

DE000MA4YB13

Delayed Börse Stuttgart 01:16:34 28/06/2024 pm IST
0.015 EUR +7.14% Intraday chart for FAKTOR-OPTIONSSCHEIN - DERMAPHARM HOLDING
1 month-12.50%
6 months-73.08%
Date Price Change
28/24/28 0.015 +7.14%
27/24/27 0.014 +7.69%
26/24/26 0.013 +8.33%
25/24/25 0.012 -14.29%
24/24/24 0.014 +16.67%

Delayed Quote Börse Stuttgart

Last update June 28, 2024 at 01:16 pm IST

More quotes

Static data

Product typeExotische Produkte
Buy / SellCALL
Underlying DERMAPHARM HOLDING SE
Issuer Morgan Stanley
WKN MA4YB1
ISINDE000MA4YB13
Date issued 10/02/2021
Strike 28.81
Maturity Unlimited
Parity 482.71 : 1
Emission price 10
Emission volume N/A
Settlement Barausgleich
Currency EUR

Technical Indicators

Highest since issue 47.41
Lowest since issue 0.008

Company Profile

Dermapharm Holding SE is a Germany-based company engaged in manufacturing of patent-free branded pharmaceuticals. The Company operates through two segments: Branded pharmaceuticals and other healthcare products, which includes in-house development, in-house production, and distribution of branded pharmaceuticals and other healthcare products, and Parallel import business, which operates under the axicorp brand. It holds around 950 marketing authorizations for more than 250 active pharmaceutical ingredients, which are marketed as pharmaceuticals, dietary supplements or supplemental balanced diets. The Company offers its products through a number of brands, including Dekristol, Ampho Moronal, Keltican, Tromcardin, among others. It is active primarily in Germany, Switzerland and Austria. Additionally, it operates production facility in Germany. Trommsdorff & GmbH Co KG is a subsidiary of the Company.
Sector
-
More about the company

Ratings for Dermapharm Holding SE

Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings

Consensus: Dermapharm Holding SE

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
36.65 EUR
Average target price
50.12 EUR
Spread / Average Target
+36.77%
Consensus